Clinical Trial Update: CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

TORL Biotherapeutics is conducting a Phase 1/2 trial (CATALINA-4) to evaluate the safety and initial efficacy of TORL-1-23 given with chemotherapy before initia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• TORL-1-23

Snippet

Sponsor: TORL Biotherapeutics, LLC | Conditions: FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers | Phase 1, Phase 2 | Status: RECRUITING